Study of exposure to substances prohibited by the World Anti-Doping Agency in healthy volunteers. Proof of concept.

2022-502216-36-00 Protocol IMIMFTCL/ESPAMA_2 Human pharmacology (Phase I) - Other Ended

Start 27 Feb 2023 · End 16 Oct 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol IMIMFTCL/ESPAMA_2

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 28
Countries 1
Sites 1

Healthy volunteers

Key facts

Sponsor
Municipal Institute Of Medical Investigation, Hospital Del Mar
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]
Trial duration
27 Feb 2023 → 16 Oct 2024
Decision date (initial)
2023-02-13
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy volunteers

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Municipal Institute Of Medical Investigation

Sponsor organisation
Municipal Institute Of Medical Investigation
Address
Calle Del Doctor Aiguader 80
City
Barcelona
Postcode
08003
Country
Spain

Scientific contact point

Organisation
Hospital Del Mar
Contact name
Ana Maria Aldea Perona

Public contact point

Organisation
Hospital Del Mar
Contact name
Ana Maria Aldea Perona

Hospital Del Mar

Sponsor organisation
Hospital Del Mar
Address
Passeig Maritim De La Barceloneta 25-29
City
Barcelona
Postcode
08003
Country
Spain

Scientific contact point

Organisation
Hospital Del Mar
Contact name
Ana Maria Aldea Perona

Public contact point

Organisation
Hospital Del Mar
Contact name
Ana Maria Aldea Perona

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 28 1
Rest of world 0

Investigational sites

Spain

1 site · Ended
Municipal Institute Of Medical Investigation
Clinical Pharmacology, Calle Del Doctor Aiguader 80, 08003, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2023-02-27 2024-10-16 2023-02-28

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2022-11-17 Spain Acceptable
2023-02-09
2023-02-13
2 SUBSTANTIAL MODIFICATION SM-2 2023-11-21 Spain Acceptable
2024-02-20
2024-02-26